Chemotherapy-Induced Nausea and Vomiting, presenting itself as one of the most distressing adverse effects of chemotherapy, is one of the main factors for the discontinuation of the chemotherapy cycles leading to poor patient compliance. Despite the fact that a complete understanding of the pathophysiology is yet to be achieved, gastrointestinal tract and Chemo trigger Zones are the two major pathways which have been identified as major drug targets to be used for the management of Chemotherapy-Induced Nausea and Vomiting.
Risk factors for CINV can be divided into patient-specific and treatment-specific risk factors. Female sex and history of motion or morning sickness are clear risk factors for nausea and vomiting. Younger age has also been correlated with increased risk, although this may be explained by the more aggressive chemotherapy regimens that tend to be administered to younger patients who have more aggressive diseases.
DelveInsight's "Chemotherapy-Induced Nausea and Vomiting (CINV) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Chemotherapy-Induced Nausea and Vomiting (CINV), historical and forecasted epidemiology as well as the Chemotherapy-Induced Nausea and Vomiting (CINV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Key Facts
Among the CINV patients, female patients have more severe and frequent chemotherapy-induced nausea and vomiting than do male patients.
In the United States, despite the use of standardized antiemetic guidelines, up to 20% of cancer patients suffer from moderate-to-severe chemotherapy-induced nausea and vomiting (CINV). It has also been observed that despite the extensive use of anti-emetics, chemotherapy-induced nausea continues to be reported by up to 70% of adult patients receiving moderately and highly emetogenic chemotherapy agents and 58% of school-age and adolescent age children receiving highly emetogenic chemotherapy.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis
Chemotherapy-Induced Nausea and Vomiting market size is anticipated to increase during the study period, 2017–2030. The key driver for the surge in market size is the rise in the number of Incident cases of Chemotherapy-Induced Nausea and Vomiting patients in 7MM.
The Chemotherapy-Induced Nausea and Vomiting (CINV) market outlook section of the report helps to build the detailed comprehension of the historic, current, and forecasted Chemotherapy-Induced Nausea and Vomiting (CINV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Chemotherapy-Induced Nausea and Vomiting (CINV) market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Chemotherapy-Induced Nausea and Vomiting (CINV) Epidemiology Forecast
The Chemotherapy-Induced Nausea and Vomiting (CINV) epidemiology section cover insights about historical and current Chemotherapy-Induced Nausea and Vomiting (CINV) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chemotherapy-Induced Nausea and Vomiting (CINV) Pipeline Analysis and Key Market Players
The Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Nausea and Vomiting (CINV) market or expected to get launched in the market during the study period. The analysis covers Chemotherapy-Induced Nausea and Vomiting (CINV) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Chemotherapy-Induced Nausea and Vomiting (CINV) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020–2030.
Some of the key players in the Chemotherapy-Induced Nausea and Vomiting (CINV) market includes:
Helsinn Healthcare
Heron Therapeutics
Novartis Therapeutics
Acacia Pharma
And many others.
For more detailed information on Chemotherapy-Induced Nausea and Vomiting (CINV) market, visit: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-market